Health Trials

Project: Every Child for Younger Patients With Cancer

ConditionsAdrenal Gland PheochromocytomaCarcinoma In SituCentral Nervous System NeoplasmChildhood Immature TeratomaChildhood Kidney NeoplasmChildhood Langerhans Cell HistiocytosisChildhood Mature TeratomaCongenital Mesoblastic NephromaDesmoid FibromatosisGanglioneuromaLymphoproliferative DisorderMalignant NeoplasmMalignant Solid NeoplasmMelanocytic NeoplasmMyeloproliferative NeoplasmNeoplasm of Uncertain Malignant PotentialNeuroendocrine NeoplasmStromal Neoplasm
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeUp to 25
SponsorChildren's Oncology Group

About this trial

This study gathers health information for the Project: Every Child for younger patients with cancer. Gathering health information over time from younger patients with cancer may help doctors find better methods of treatment and on-going care.

Eligibility criteria

Qualifiers

Enrollment must occur within 6 months of initial disease presentation OR within 6 months of refractory disease, disease progression, disease recurrence, second or secondary malignancy, or post-mortem

Patients previously enrolled on ACCRN07 are eligible to enroll on Tracking Outcome, Registry and Future Contact components of APEC14B1 any time after they reach age of majority

All cancer cases with an International Classification of Diseases for Oncology (ICD-O) histologic behavior code of one "1" (borderline), two "2" (carcinoma in situ) or three "3" (malignant)

All neoplastic lesions of the central nervous system regardless of behavior, i.e., benign, borderline or malignant

Disqualifiers

None

Trial design

Treatments tested in this trial

  • Cytology Specimen Collection Procedure
  • Medical Chart Review

Treatment groups

75,000 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Children's Oncology Group

Lead sponsor

National Cancer Institute (NCI)

Collaborator

Source ClinicalTrials.gov